SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Injective taken over by the community.

Nonja

NONJA is trending as a top meme coin on the Injective blockchain, driven by its resilient, unruggable nature and dedicated community. Enthusiasts view it as a leveraged bet on $INJ's significant undervaluation, strong fundamentals, and anticipated institutional interest via upcoming staked ETFs.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT CRYPTO) is actively discussed, with a community divided between those optimistic about its long-term move-to-earn utility and potential for a technical breakout, and others noting its historical decline and questioning its value.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending as its community actively engages with the playful "Whats UpDog?" meme, highlighting its longevity as a Solana-based token while encouraging users to load bags and embrace its unique brand of humor.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amidst heightened buyout speculation, with French reports citing interest from Eli Lilly and AstraZeneca for its promising ulcerative colitis drug, obefazimod, further bolstered by recent data on its anti-fibrotic activity at ECCO 2026; the community is keenly debating potential acquisition valuations and comparing its trajectory to past biotech successes.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively trending following FDA approval of BYSANTI for bipolar I disorder and schizophrenia, which the community sees as a significant rerating catalyst due to its long patent protection. Investors are further speculating on a potential buyout, driven by the broader pipeline's "mega blockbuster" potential, particularly Tradipitant for GLP-1 induced nausea.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as its notable price declines and underperformance spark community frustration, while long-term holders maintain conviction, emphasizing its potential through Real-World Asset tokenization, recent ETF developments, and anticipated regulatory clarity.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending as the community highlights its pivotal role in AI and cross-chain interoperability, driven by developments like its integration with Starknet and Solana via NEAR Intents, and participation in the NVIDIA Inception Program. Growing user adoption, recent tokenomics adjustments, and a Grayscale Trust filing further underscore its positioning as a significant force in the web3 ecosystem.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is trending due to strong quarterly results and an upbeat outlook, with community discussion focusing on how its growing portfolio of new drugs and recent regulatory milestones, including a priority review for a multiple myeloma therapy, are positioned to counter upcoming patent challenges and present a compelling value.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending as a "SaaSpocalypse" narrative, driven by fears that AI models like Anthropic's Claude will disrupt and replace traditional software, has led to a significant sell-off. However, the community widely views this as an illogical overreaction, asserting that established software companies will integrate AI to enhance their strong fundamentals, rather than be displaced.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending amidst heated community debate regarding the Algorand Foundation's financial sustainability and perceived mismanagement, with concerns about potential token supply increases contrasting sharply against hopes for regulatory clarity and a broader altcoin market recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WMT Q4 &#39;24 Earnings Results &amp; Recap 
 
Walmart&#39;s actual Q4 EPS of $0.66 exceeded the estimate of $0.65 and revenue of $180.55B was higher than the $180.07B estimate.  The company projects full-year 2026 sales growth of 3-4% and operating income growth faster than sales at 3.5-5.5%.

Noah Loffredo

morgan

Geeky_Greg

Willie Watson

Stephanie Torres

Etta Palmer

Ethan Woods

Jake Summers

Christopher Ward

StockTwits for iOS

Ramesh Gaddam

profitbydre.eth

StockTwits Web

Stocktwits

Walmart Inc

 Q4 '24 Earnings Results & Recap 
 
Walmart's actual Q4 EPS of $0.66 exceeded the estimate of $0.65 and revenue of $180.55B was higher than the $180.07B estimate.  The company projects full-year 2026 sales growth of 3-4% and operating income growth faster than sales at 3.5-5.5%.